Senior Director, Drug Product CMC
Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company · Boston, MA
Posted 29 days ago · $160,000.00 to $250,000.00 · Previously reposted
or apply directly on Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company 's site. We never take the application ourselves.
Is this posting real?
- This role has been open
- 29 days Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company 's roles stay open a median of 21 days
- Reposted
- Yes taken down and listed again at least once
- Salary listed
- Yes 90% of Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company 's roles list one
- Ghost-job risk at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company
- low 3 stale, 10 reposted of 21 open
- Hiring momentum
- 31 roles opened in the last 90 days ↑ up vs. the prior 90 days
- Last confirmed on the employer's board
- 2026-09-17
Measured from postings appearing on and disappearing from Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company 's own greenhouse board since 2026-08-03. Full hiring picture for Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company .
About this role
The Senior Director of Drug Product CMC at Centessa Pharmaceuticals will lead the development of nonclinical and clinical formulations for small molecule drug products, managing external vendors such as CROs and CDMOs. The role involves overseeing formulation development, conducting stability studies, and supporting regulatory submissions, while collaborating with cross-functional teams to meet project timelines and deliverables.
- benefits
- 3/5
- freshness
- 4/5
- career value
- 4/5
- role clarity
- 5/5
- pay transparency
- 5/5
Scored from the posting itself — how clearly the role is described, how much it says about pay and benefits, and how recently it was listed. Not a judgement of Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company as an employer.
What you need
- Advanced degree in Chemistry, Pharmaceutical Sciences, or a related discipline; Ph.D. strongly preferred
- 10+ years of drug product/formulation development experience supporting nonclinical and clinical programs
- Expertise across oral, subcutaneous, and intravenous dosage forms for small molecules
- Deep technical expertise in the development and manufacture of poorly soluble compounds
- Strong understanding of pharmaceutical sciences and engineering principles related to dosage form development
- Working knowledge of analytical and solid-state characterization techniques
What you get
- Annual base salary range of $160,000.00 to $250,000.00
- Discretionary annual bonus
- Comprehensive benefits package including 401(k) plan
- Company-sponsored medical, dental, vision, and life insurance
- Generous paid time off
- Health and wellness program
Worth weighing
- Travel to domestic and international vendors required
- Role involves managing external vendors, which may add complexity to project management
- Fast-paced environment may require strong prioritization and resource management skills
Summarised from Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company 's posting. Read the full original.
Listed by Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company on their greenhouse job board, last confirmed open on 2026-09-17. PitchMeAI is not the employer.
More roles at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company
- Senior Director, Analytical Development CMCBoston, MA
- Associate Director, Project ManagementBoston, MA
- Associate Project Manager, Drug DevelopmentBoston, MA
- Senior Advisor, Regulatory Starting MaterialBoston, MA
- Senior Advisor, Manufacturing Package DesignBoston, MA
- Director, Quality Control (contractor)Boston, MA
- Inventory Control Manager, Supply Chain (contractor)Boston, MA
- Director, Supplier Quality, Inspection & Audit (contractor)Boston, MA
All 21 open roles at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company →